JPRN-UMIN000034131已完成未知
A Retrospective Multicenter Analysis of PD-L1 expression in Japanese Renal Cell Carcinoma patients - A Retrospective Multicenter Analysis of PD-L1 expression in Japanese Renal Cell Carcinoma patients (CMA-Ate004)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 830
研究概览
简要总结
American Association for Cancer Research Annual Meeting 2020
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Malignancies other than RCC is co-existed during the time from nephrectomy and death. 2.Treatment with anti-CTLA-4 antibody, anti-PD-1/PD-L1 antibodies as first-line therapy for recurrent or metastatic RCC.
研究者
相似试验
已完成
不适用
Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression.Lung CancerNCT02785562Groupe Francais De Pneumo-Cancerologie170
已完成
不适用
Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)Large Cell Lung CancerNeuroendocrine Carcinoma of Lung (Diagnosis)NCT03305133Groupe Francais De Pneumo-Cancerologie86
已完成
不适用
SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)Squamous Cell Carcinoma of the Head and NeckNCT02543476AstraZeneca412
已完成
1 期
A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer PatientsAdvanced Solid TumorsNCT03133247Atridia Pty Ltd.37
进行中（未招募）
1 期
A study of CX-072 in Combination with other Anticancer Therapy in Adults with Solid TumorsEUCTR2019-000999-42-GBCytomX Therapeutics, Inc162